Cancer News and Research

Latest Cancer News and Research

Bacteria barge inside guard cells and initiate a powerful immune response

Immune cells that are the body's front-line defense don't necessarily rest quietly until invading bacteria lock onto receptors on their outside skins and rouse them to action, as previously thought.

18 Apr 2007

Nanoparticles could damage DNA and lead to cancer

Tissue studies indicate that nanoparticles, engineered materials about a billionth of a meter in size, could damage DNA and lead to cancer, according to research presented at the 2007 Annual Meeting of the American Association for Cancer Research.

18 Apr 2007

Aspirin may modestly reduce cancer risk

A daily dose of adult-strength aspirin may modestly reduce cancer risk in populations with high rates of colorectal, prostate, and breast cancer if taken for at least five years.

18 Apr 2007

Lexicon Reports on anti-angiogenesis target discoveries

Lexicon Genetics has presented results from the company's genetic screen to identify proteins involved in blood vessel formation and organization.

18 Apr 2007

Nanoparticle delivery system delivers cancer-suppressing gene in M. D. Anderson trial

A cancer-suppressing gene has been successfully delivered into the tumors of stage 4 lung cancer patients via an intravenously administered lipid nanoparticle in a phase I clinical trial at The University of Texas M. D. Anderson Cancer Center.

18 Apr 2007

Immunomedics presents results on novel immunotoxin for prostate and lung cancers

Immunomedics has presented at the 2007 Annual Meeting of the American Association for Cancer Research results on the in vitro and in vivo evaluation of a novel immunotoxin, Rap-hRS7, for the potential treatment of prostate and lung cancers.

18 Apr 2007

New vaccine strategy for head and neck cancers

Most attempts to create therapeutic cancer vaccines are based on custom-made approaches that use a patient's own tumor cells to generate a strong immune response against cancer.

18 Apr 2007

More effective therapies for individual cancers - personalized medicine

Genetic and epigenetic variations ensure that no two people are exactly alike, and the same holds true for any two cancers.

18 Apr 2007

Aspirin, cancer and lung inflamation

Two new studies by researchers at the at the Mayo Clinic have found that taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) on a regular basis may offer some protection against cancer.

18 Apr 2007

Scientists tackle cancer with different approaches

Studies presented at the 2007 meeting of the American Association for Cancer Research show how researchers are using the new, as well as the natural, to help design and test new drugs to treat cancer.

18 Apr 2007

Early stage pancreatic cancer expresses antigen targeted by Immunomedics' PAM4 antibody

Immunomedics has reported in an oral presentation at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) that the antigen targeted by the humanized PAM4 antibody is expressed in early stage pancreatic cancer specimens, a stage before the tumor becomes invasive.

18 Apr 2007

Polymorphisms in the glutathione S-transferase genes and treatment outcomes in acute myeloid leukemia

Levels of an enzyme involved metabolizing chemotherapy may help patients with acute myeloid leukemia (AML) to be able to better tolerate chemotherapy, according to the results of research which will be presented by Kirsten Moysich, PhD, Department of Epidemiology, Roswell Park Cancer Institute (RPCI) at the 2007 centennial meeting of the American Association for Cancer Research (AACR), April 14-18, in Los Angeles, CA.

18 Apr 2007

Scientists isolate enzyme that could be used to predict survival for nasopharyngeal cancer

Mayo Clinic Cancer Center scientists, in collaboration with Chinese researchers, have isolated an enzyme that could be used to predict survival and recurrence rates for nasopharyngeal cancer -- a common cancer affecting people from Southeast Asia.

18 Apr 2007

Cell Therapeutics settles law suit with Government

Cell Therapeutics has announced that it has settled all government claims arising out of a Department of Justice investigation into allegations regarding alleged overpayments by Medicare to doctors who prescribed the anti-cancer drug, TRISENOX.

18 Apr 2007

Cell Genesys reports data from clinical trials of GVAX immunotherapy for prostate cancer

Evaluation of antibody responses in patients with advanced prostate cancer from these studies shows that the GVAX cell-based immunotherapy induces antibody responses to a broad array of prostate cancer- associated antigens, including some not previously known to be associated with prostate cancer.

18 Apr 2007

Taking a jab at cancer by stimulating the immune system

As the first FDA-approved cancer vaccine, designed to protect against human papillomavirus, has moved from scientific discussion to social debate, other vaccine studies are continuing to make progress.

18 Apr 2007

Studies highlight role of inflammation in cancer

Can reducing inflammation keep cancer at bay? Two novel studies presented at the 2007 Annual Meeting of the American Association for Cancer Research that examine use of common anti-inflammatory agents suggest this might be the case.

18 Apr 2007

Cancer patients are at high risk for potential drug interactions

Potential drug interactions from prescribed medications are common among cancer patients and may cause unnecessary harm, according to a study in the April 18 Journal of the National Cancer Institute .

18 Apr 2007

Avalon Pharmaceuticals announces results of AVN944 biomarker study

Avalon Pharmaceuticals has announced the results of an AVN944 biomarker study that utilized Avalon's proprietary AvalonRx technology to identify gene signatures that may be useful for patient stratification.

18 Apr 2007

Anadys Pharmaceuticals presents data showing ANA773 promotes anti-tumor activity of killer cells

Anadys Pharmaceuticals presented data from an in vitro study showing that the active metabolite of ANA773 promotes natural killer (NK) cell-mediated anti-tumor response by inducing cytokine secretion, cytolysis of tumor cells and enhanced antibody-dependent cellular cytotoxicity (ADCC), during a poster presentation at the Annual Meeting of the American Association of Cancer Research (AACR) in Los Angeles.

18 Apr 2007